http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-599373-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-186 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5767 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-569 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-576 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2010-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad05ad86a1e569096c38572e09797919 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e3b175035ef86883a330155773931db |
| publicationDate | 2013-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NZ-599373-A |
| titleOfInvention | Biomarkers for predicting rapid response to hcv treatment |
| abstract | Patent No. 599373 Disclosed is a method for predicting that a human subject infected with Hepatitis C Virus Genotype 1(HCV-l) or Hepatitis C Virus Genotype 4 (HCV-4) will achieve Rapid Virologic Response-2 Weeks (RVR2) to treatment with pegylated interferon alpha, ribavirin and a HCV NSSB polymerase inhibitor selected from the group consisting of (i) Isobutyric acid (2R,3S,4R,SR)-S-(4-amino-2-oxo-2H-pyrimidin-1-yl)-2-azido-3,4-bis-isobutyryloxy-tetrahydro-furan-2-ylmethyl ester (R04S88161), (ii) Isobutyric acid (2R,3R,4R,SR)-5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-4-fluoro-3-isobutyryloxy-4-methyl-tetrahydro-furan-2-ylmethyl ester (RO5024048), and (iii) pharmaceutically acceptable acid addition salts of (i) and (ii), the method comprising: (i) determining the expression level in a sample isolated from said subject prior to said treatment of at least one protein selected from the group consisting of MDC, Eotaxin, ILlO, TARC, and MCP1, and (ii) comparing the expression level of the at least one protein in said sample to a reference value representative of an expression level of the at least one protein derived from pre-treatment samples of a patient population that did not achieve RVR2 to said treatment; wherein a statistically significant higher expression level ofthe at least one protein in said sample is indicative that said subject will achieve RVR2 to said treatment. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2557534-C2 |
| priorityDate | 2009-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 48.